Treatment of Chronic Akinetic Mutism With Atomoxetine: Subtraction Analysis of Brain F-18 Fluorodeoxyglucose Positron Emission Tomographic Images Before and After Medication: A Case Report
Uloženo v:
| Název: | Treatment of Chronic Akinetic Mutism With Atomoxetine: Subtraction Analysis of Brain F-18 Fluorodeoxyglucose Positron Emission Tomographic Images Before and After Medication: A Case Report |
|---|---|
| Autoři: | Ji Cheol Shin, Young-Sil An, Yong Wook Kim |
| Přispěvatelé: | Yong Wook Kim, Ji-Cheol Shin, Young-sil An, Kim, Yong Wook, Shin, Ji Cheol |
| Zdroj: | Clinical Neuropharmacology. 33:209-211 |
| Informace o vydavateli: | Ovid Technologies (Wolters Kluwer Health), 2010. |
| Rok vydání: | 2010 |
| Témata: | Occipital Lobe/metabolism, Male, Frontal Lobe/metabolism, Time Factors, Propylamines/therapeutic use, Akinetic Mutism/drug therapy, Aneurysm, Ruptured, Atomoxetine Hydrochloride, 03 medical and health sciences, Cognition, 0302 clinical medicine, Fluorodeoxyglucose F18, Cognition/drug effects, Glucose/metabolism, Occipital Lobe/diagnostic imaging, Humans, Frontal Lobe/diagnostic imaging, Occipital Lobe/drug effects, Akinetic Mutism/metabolism, Ruptured/complications, Norepinephrine Plasma Membrane Transport Proteins, Subarachnoid Hemorrhage/etiology, Propylamines, Akinetic Mutism/diagnostic imaging, Fluorodeoxyglucose F18/metabolism, Middle Aged, Subarachnoid Hemorrhage, Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors, Aneurysm, Frontal Lobe, 3. Good health, Akinetic Mutism, Glucose, Frontal Lobe/drug effects, Positron-Emission Tomography, Subtraction Technique, akinetic mutism, Occipital Lobe, atomoxetine |
| Popis: | Akinetic mutism is a rare, complex neuropathologic disorder. The pharmaceutical treatment of akinetic mutism typically includes dopaminergic agents, but the resulting therapeutic effects are often unsatisfactory, and it remains unclear whether late treatment using these medications is effective. We present a case study of a 53-year-old male patient who developed akinetic mutism for a period of 7 months after a subarachnoid hemorrhage. The hemorrhage was caused by a ruptured aneurysm in the right anterior communicating artery, followed by a secondary infarction in the territory of the right anterior cerebral artery. Baseline brain F-18 fluorodeoxyglucose positron emission tomographic images revealed decreased glucose metabolism in both frontal lobes. Treatment with atomoxetine, a selective norepinephrine reuptake inhibitor, for a period of 8 weeks led to a clinically significant improvement in the patient's cognitive function and activities of daily living. A subtraction brain positron emission tomographic analysis after atomoxetine medication revealed increased cerebral glucose metabolism in both the premotor and visual association cortices. Thus, we suggest that atomoxetine can be a useful therapeutic option in the treatment of chronic akinetic mutism. |
| Druh dokumentu: | Article |
| Popis souboru: | 209~211 |
| Jazyk: | English |
| ISSN: | 0362-5664 |
| DOI: | 10.1097/wnf.0b013e3181dca948 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/20661027 https://www.ncbi.nlm.nih.gov/pubmed/20661027 https://pubmed.ncbi.nlm.nih.gov/20661027/ https://ir.ymlib.yonsei.ac.kr/handle/22282913/101391 https://europepmc.org/article/MED/20661027 |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....8f6093b76f965728f296998927cd70ef |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Akinetic mutism is a rare, complex neuropathologic disorder. The pharmaceutical treatment of akinetic mutism typically includes dopaminergic agents, but the resulting therapeutic effects are often unsatisfactory, and it remains unclear whether late treatment using these medications is effective. We present a case study of a 53-year-old male patient who developed akinetic mutism for a period of 7 months after a subarachnoid hemorrhage. The hemorrhage was caused by a ruptured aneurysm in the right anterior communicating artery, followed by a secondary infarction in the territory of the right anterior cerebral artery. Baseline brain F-18 fluorodeoxyglucose positron emission tomographic images revealed decreased glucose metabolism in both frontal lobes. Treatment with atomoxetine, a selective norepinephrine reuptake inhibitor, for a period of 8 weeks led to a clinically significant improvement in the patient's cognitive function and activities of daily living. A subtraction brain positron emission tomographic analysis after atomoxetine medication revealed increased cerebral glucose metabolism in both the premotor and visual association cortices. Thus, we suggest that atomoxetine can be a useful therapeutic option in the treatment of chronic akinetic mutism. |
|---|---|
| ISSN: | 03625664 |
| DOI: | 10.1097/wnf.0b013e3181dca948 |